therapeutic based on CMP-nonulosonate sugars
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Dec 15, 2020
Grant Date -
Dec 21, 2017
app pub date -
Sep 1, 2017
filing date -
Feb 20, 2014
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
N. gonorrhoeae has become resistant to almost every conventional antibiotic. Described herein is the use of CMP-nonulosonate analogues to counter gonococcal complement evasion. The nonulosonate sugar is incorporated into the lipooligosaccharide of the N. gonorrhoeae which in turn reduces the serum resistance of the bacteria. This provides a novel therapeutic strategy against the global threat of multi-drug resistant gonorrhea.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully